Cumulative Signaling Through NOD-2 and TLR-4 Eliminates the


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2021
Historique:
received: 18 02 2021
accepted: 21 06 2021
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 31 7 2021
Statut: epublish

Résumé

For a long time, tuberculosis (TB) has been inflicting mankind with the highest morbidity and mortality. Although the current treatment is extremely potent, a few bacilli can still hide inside the host mesenchymal stem cells (MSC). The functional capabilities of MSCs are known to be modulated by TLRs, NOD-2, and RIG-1 signaling. Therefore, we hypothesize that modulating the MSC activity through TLR-4 and NOD-2 can be an attractive immunotherapeutic strategy to eliminate the

Identifiants

pubmed: 34307192
doi: 10.3389/fcimb.2021.669168
pmc: PMC8294323
doi:

Substances chimiques

NOD2 protein, human 0
Nod2 Signaling Adaptor Protein 0
TLR4 protein, human 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

669168

Informations de copyright

Copyright © 2021 Aqdas, Singh, Amir, Maurya, Pahari and Agrewala.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Exp Med. 2009 Aug 3;206(8):1709-16
pubmed: 19581406
Tuberculosis (Edinb). 2004;84(1-2):29-44
pubmed: 14670344
Stem Cells. 2006 Dec;24(12):2744-52
pubmed: 16902195
Sci Rep. 2017 Nov 8;7(1):15010
pubmed: 29118429
J Clin Immunol. 2015 Jan;35(1):1-10
pubmed: 25312698
Infect Immun. 2007 Jan;75(1):270-7
pubmed: 17074860
Am J Pathol. 2014 Dec;184(12):3170-5
pubmed: 25451154
Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1900-9
pubmed: 16648192
Immunol Cell Biol. 2007 Feb-Mar;85(2):103-11
pubmed: 17213830
Clin Dev Immunol. 2011;2011:405310
pubmed: 21603213
J Clin Invest. 2004 Dec;114(12):1790-9
pubmed: 15599404
Curr Opin Infect Dis. 2008 Jun;21(3):279-86
pubmed: 18448973
J Exp Med. 1990 Sep 1;172(3):977-80
pubmed: 2117640
Microbes Infect. 2003 Feb;5(2):151-8
pubmed: 12650773
Nat Immunol. 2004 Oct;5(10):971-4
pubmed: 15454919
Expert Rev Mol Med. 2011 Dec 16;13:e39
pubmed: 22172201
Shock. 2013 Dec;40(6):451-62
pubmed: 23989337
Lancet Infect Dis. 2016 Apr;16(4):e47-63
pubmed: 27036359
PLoS Med. 2007 Jul 24;4(7):e238
pubmed: 17676945
J Neurochem. 2009 Jun;109(6):1791-9
pubmed: 19457134
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1464-9
pubmed: 23297218
Am J Pathol. 2015 Jul;185(7):1924-34
pubmed: 26066709
Nat Protoc. 2009;4(1):102-6
pubmed: 19131962
Cell Mol Life Sci. 2013 Jan;70(1):89-103
pubmed: 22669258
Front Cell Dev Biol. 2020 Jul 08;8:561
pubmed: 32733882
Int J Infect Dis. 2020 Mar;92S:S69-S71
pubmed: 32119979
Sci Rep. 2016 Mar 16;6:23089
pubmed: 26980157
Sci Rep. 2016 Jan 12;6:19084
pubmed: 26754352
Cell Immunol. 2011;271(1):147-56
pubmed: 21757189
Immune Netw. 2017 Apr;17(2):89-102
pubmed: 28458620
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
Drugs. 2014 Jul;74(10):1063-72
pubmed: 24962424
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3168-76
pubmed: 23093667
Mucosal Immunol. 2020 Mar;13(2):190-204
pubmed: 31772320
Blood. 2007 Feb 15;109(4):1422-32
pubmed: 17038530
Lancet. 2014 Mar 22;383(9922):1016-8
pubmed: 24656187
Expert Opin Drug Saf. 2006 Mar;5(2):231-49
pubmed: 16503745
Sci Transl Med. 2013 Jan 30;5(170):170ra13
pubmed: 23363977
Sci Rep. 2016 Jun 06;6:27263
pubmed: 27265209
Front Immunol. 2012 Jul 02;3:182
pubmed: 22783256
Cell Microbiol. 2010 Aug;12(8):1026-35
pubmed: 20557314
J Innate Immun. 2016;8(3):228-42
pubmed: 26613532
J Immunol. 2008 Nov 15;181(10):7157-65
pubmed: 18981137
J Orthop Translat. 2014 Aug 27;3(1):26-33
pubmed: 30035037
Autophagy. 2020 Jun;16(6):1021-1043
pubmed: 31462144
Int Immunol. 2005 Jan;17(1):1-14
pubmed: 15585605
Sci Rep. 2016 Dec 21;6:39492
pubmed: 28000752
Curr Opin Microbiol. 2013 Feb;16(1):78-84
pubmed: 23290190
Microbiol Spectr. 2019 Jul;7(4):
pubmed: 31298204
PLoS One. 2010 Apr 26;5(4):e10088
pubmed: 20436665
PLoS One. 2010 Oct 22;5(10):e15369
pubmed: 21042538
Cell Death Dis. 2013 Dec 12;4:e967
pubmed: 24336087
Microbes Infect. 2003 Jun;5(7):621-7
pubmed: 12787738
Immunity. 2002 Mar;16(3):429-39
pubmed: 11911827
Stem Cells Dev. 2019 May 1;28(9):620-631
pubmed: 30808255

Auteurs

Mohammad Aqdas (M)

Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology, Chandigarh, India.

Sanpreet Singh (S)

Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology, Chandigarh, India.

Mohammed Amir (M)

Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology, Chandigarh, India.

Sudeep Kumar Maurya (SK)

Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology, Chandigarh, India.

Susanta Pahari (S)

Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology, Chandigarh, India.

Javed Naim Agrewala (JN)

Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology, Chandigarh, India.
Immunology Laboratory, Center for Biomedical Engineering, Indian Institute of Technology, Ropar, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH